Stock Events

Stock Events

Corcept Therapeutics 

$40.31
112
+$2.19+5.75% Tuesday 20:00

Statistics

Day High
40.35
Day Low
38.5
52W High
114.71
52W Low
28.66
Volume
1,488,096
Avg. Volume
2,203,298
Mkt Cap
4.29B
P/E Ratio
65.6
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.11
0.07
0.25
0.43
Expected EPS
-0.10849
Actual EPS
N/A

Financials

13.09%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
1.52BRevenue
199.3MNet Income

Analyst Ratings

$88.33Average Price Target
The highest estimate is 110.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
50%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CORT. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie competes in the pharmaceuticals space, focusing on therapies that could directly compete with Corcept's treatments in endocrine and metabolic diseases.
Pfizer
PFE
Mkt Cap140.15B
Pfizer operates in various therapeutic areas, including endocrinology, potentially competing with Corcept's hormone-related therapies.
Merck
MRK
Mkt Cap214.76B
Merck is involved in developing medications for a wide range of conditions, including those that could compete with Corcept's focus areas.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb develops drugs in multiple therapeutic areas, including those that could compete with Corcept's products in hormonal and metabolic diseases.
Novartis
NVS
Mkt Cap237.61B
Novartis offers a broad portfolio of drugs, including treatments for endocrine disorders, directly competing with Corcept's market.
AMGEN
AMGN
Mkt Cap160.66B
Amgen focuses on innovative therapeutics, including endocrine and metabolic disorders, which could compete with Corcept's therapies.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, known for its work in antiviral drugs, also explores treatments in other areas that could compete with Corcept's focus on metabolic and endocrine disorders.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals focuses on developing drugs for a wide range of diseases, including potential competition in the endocrine and metabolic disorder space.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals engages in creating treatments for serious diseases, potentially including those that compete with Corcept's niche in hormonal therapies.

About

Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Show more...
CEO
Dr. Joseph K. Belanoff M.D.
Employees
500
Country
US
ISIN
US2183521028

Listings

MI
IT
1CORT.MI
BOATS
BOATS
CORT.BOATS
LSE
GB
0I3Q.LSE
XNAS
US
CORT

0 Comments

Share your thoughts

FAQ

What is Corcept Therapeutics stock price today?▼
The current price of CORT is $40.31 USD — it has increased by +5.75% in the past 24 hours. Watch Corcept Therapeutics stock price performance more closely on the chart.
What is Corcept Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Corcept Therapeutics stocks are traded under the ticker CORT.
Is Corcept Therapeutics stock price growing?▼
CORT stock has fallen by -0.4% compared to the previous week, the month change is a +12.91% rise, over the last year Corcept Therapeutics has showed a -56.15% decrease.
What is Corcept Therapeutics market cap?▼
Today Corcept Therapeutics has the market capitalization of 4.29B
When is the next Corcept Therapeutics earnings date?▼
Corcept Therapeutics is going to release the next earnings report on May 06, 2026.
What were Corcept Therapeutics earnings last quarter?▼
CORT earnings for the last quarter are 0.2 USD per share, whereas the estimation was 0.33 USD resulting in a -39.3% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Corcept Therapeutics revenue for the last year?▼
Corcept Therapeutics revenue for the last year amounts to 1.52B USD.
What is Corcept Therapeutics net income for the last year?▼
CORT net income for the last year is 199.3M USD.
How many employees does Corcept Therapeutics have?▼
As of April 01, 2026, the company has 500 employees.
In which sector is Corcept Therapeutics located?▼
Corcept Therapeutics operates in the Health Care sector.
When did Corcept Therapeutics complete a stock split?▼
Corcept Therapeutics has not had any recent stock splits.
Where is Corcept Therapeutics headquartered?▼
Corcept Therapeutics is headquartered in Redwood City, US.